Naviscan touts clinical study results
Article Thumbnail ImageJuly 25, 2013 -- PET developer Naviscan is highlighting clinical trial results that show positron emission mammography (PEM) imaging with a breast-cancer-specific tracer achieved 100% sensitivity.

To get access to this article and all of the content on, create a free account or sign-in now.
Member Sign In:
  MemberID or E-mail Address:

New Members

Becoming a Member is FREE!

  • Real-time radiology-specific news
  • Case of the Day and Teaching Files
  • Focused topics digital communities
  • Lively, discussion groups
  • Medical imaging bookstore
  • SalaryScan
  • Job Boards
  • Online CME
  • Bookstore, market reports, more …
  • Conference Calendar
  • User-controlled eNewsletters
  • … registration is FREE and easy!
  • Mathew Thakur, PhD, of Thomas Jefferson University, and colleagues performed PEM imaging using both the cancer-specific radiotracer copper-64 (Cu-64) TP3805 and F-18 FDG in 13 patients. Results were published in the July issue of the Journal of Nuclear Medicine (Vol. 54:7, pp. 1019-1025).

    PEM with TP3805 identified all of the 20 malignant lesions in the patient cohort, according to Naviscan. The images were acquired with Naviscan's PET scanner

    TP3805 is licensed by NuView Life Sciences. It binds to receptors found on all breast cancer cells early in malignant transformation, Naviscan said.

    || About || Advertising || || Bookstore || Breast MRI || Career Center || Case of the Day || Communities || Conferences || Contact Us || ECR News 2013 || Education || Equipment Classifieds || Facebook || Forums || Home || Links || Marketplace || Middle East || Mobile || Molecular Breast Imaging || New Installations || News in Brief || People in the News || Privacy Policy || RSNA News 2013 || Reference || Salary Survey Results || Trends in Radiology || Twitter || Vendor Connect || Webinars || XML/RSS ||

    Copyright © 2014 All Rights Reserved.